List of Excipients in Branded Drug WAL-ITIN

« Back to Dashboard

Generic Drugs Containing WAL-ITIN

Company	Ingredient	NDC	Excipient
Walgreens	loratadine	0363-0754	ANHYDROUS CITRIC ACID
Walgreens	loratadine	0363-0754	ASPARTAME
Walgreens	loratadine	0363-0754	CELLULOSE, MICROCRYSTALLINE
Walgreens	loratadine	0363-0754	COCHINEAL
Walgreens	loratadine	0363-0754	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in WAL-ITIN?

# Of NDCs	Excipient
2	ANHYDROUS CITRIC ACID
2	ASPARTAME
1	CAPRYLIC/CAPRIC MONO/DIGLYCERIDES
3	CELLULOSE, MICROCRYSTALLINE
1	COCHINEAL

WAL-ITIN Excipient Strategy and Commercial Opportunities for Loratadine

Last updated: October 21, 2026

WAL-ITIN is a Walgreens private-label loratadine allergy product. Its commercial value comes from low-cost OTC distribution, retailer control, and formulation extensions rather than active-ingredient patent protection. The strongest excipient opportunities are differentiated oral formats, improved swallowability, pediatric dosing, rapid disintegration, packaging stability, and allergen-conscious positioning.

What is WAL-ITIN and which active ingredient does it contain?

WAL-ITIN is associated with loratadine, a second-generation antihistamine used for temporary relief of allergy symptoms, including sneezing, runny nose, itchy or watery eyes, and itching of the nose or throat. Standard adult dosing is typically 10 mg once daily, subject to the applicable product labeling.[1]

Loratadine was commercialized by Schering-Plough under the Claritin brand. The active ingredient is now widely available through generic and private-label OTC products. The product category includes conventional tablets, orally disintegrating tablets, chewable tablets, syrups, and combination allergy products.

Attribute	WAL-ITIN commercial profile
Active ingredient	Loratadine
Therapeutic class	Second-generation H1 antihistamine
Typical adult strength	10 mg
Regulatory category	OTC drug
Primary channel	Walgreens retail and digital channels
Reference branded product	Claritin
Patent position	Core active-ingredient exclusivity has expired
Main commercial battleground	Price, format, packaging, availability, and retailer placement
Primary formulation opportunity	Better patient experience without changing the labeled dose

The exact excipient composition can differ by dosage form, manufacturer, supplier, and package configuration. A WAL-ITIN tablet, chewable tablet, orally disintegrating tablet, or liquid should be treated as a separate formulation for excipient, stability, labeling, and manufacturing analysis.

What excipients are likely to be used in WAL-ITIN tablets?

A conventional loratadine tablet generally requires excipients for dilution, binding, disintegration, lubrication, flow control, taste management, and physical stability. Typical candidates include microcrystalline cellulose, lactose or another diluent, croscarmellose sodium or sodium starch glycolate, colloidal silicon dioxide, and magnesium stearate.

Because loratadine is a low-dose active ingredient, content uniformity is a central manufacturing requirement. The excipient system must distribute a small quantity of loratadine consistently through the tablet blend. Blend segregation, electrostatic behavior, particle-size differences, and lubrication time can affect dose uniformity and dissolution.

Excipient function	Common candidate classes	Strategic purpose
Diluent	Microcrystalline cellulose, lactose, mannitol, dibasic calcium phosphate	Provides tablet mass and supports compression
Binder	Pregelatinized starch, povidone, hydroxypropyl cellulose	Improves granule and tablet integrity
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Controls tablet breakup and dissolution
Glidant	Colloidal silicon dioxide	Improves powder flow and blend uniformity
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces friction during compression and ejection
Sweetener	Sucralose, aspartame, acesulfame potassium, sugar alcohols	Supports chewable or orally disintegrating formats
Flavor	Mint, grape, berry, citrus	Improves pediatric and chewable acceptance
Film coating	Hypromellose, polyethylene glycol, titanium dioxide or approved colorants	Supports appearance, identification, and swallowability

The commercial objective is not to maximize the number of excipients. A lower-complexity formula can reduce cost, shorten scale-up, and simplify supplier qualification. The better strategy is to match the excipient system to the intended format and consumer problem.

What excipient strategy is strongest for conventional WAL-ITIN tablets?

For a standard swallowable 10 mg tablet, the preferred strategy is a robust, low-cost direct-compression or dry-granulation formula with reliable content uniformity and fast disintegration.

A practical base formula would use:

• Microcrystalline cellulose or a cellulose-lactose combination as the primary diluent.
• Croscarmellose sodium or crospovidone as the principal disintegrant.
• Colloidal silicon dioxide to improve flow.
• Magnesium stearate at a controlled concentration and blending time.
• A thin film coating for color, identification, and swallowability.

The main development risks are over-lubrication, poor blend uniformity, low tablet tensile strength, excessive friability, and dissolution variability. Magnesium stearate can reduce wettability when used excessively or blended for too long. A high disintegrant level can improve breakup but may reduce compactibility or increase tablet expansion.

A retailer private-label product usually benefits from a standard excipient platform shared across multiple strengths or allergy products. Common tooling, common packaging, and common manufacturing processes reduce inventory and quality-system costs.

What formulation patents could protect WAL-ITIN extensions?

The broad loratadine active ingredient is not the principal source of protection. Potentially protectable subject matter would involve a specific formulation, manufacturing process, delivery system, or combination of technical parameters.

Potential formulation patent concepts include:

1. An orally disintegrating loratadine tablet with defined disintegration time and mechanical strength.
2. A taste-masked chewable formulation using a coated loratadine particle or ion-exchange complex.
3. A low-moisture composition that improves chemical stability.
4. A liquid formulation with defined solubilization and preservative characteristics.
5. A multiparticulate or rapidly dissolving dosage form with a specified particle-size distribution.
6. A process that improves content uniformity at low drug loading.
7. A combination product with a defined ratio of loratadine and another OTC active ingredient, subject to FDA requirements.

Patent strength would depend on claim breadth, reproducibility, unexpected performance, and the distance from known loratadine formulations. A claim limited to routine substitution of one common diluent for another would generally face stronger obviousness risk than a composition linked to measurable stability, dissolution, taste, or manufacturability improvements.

How can excipients create commercial opportunities for WAL-ITIN?

Orally disintegrating tablets

An orally disintegrating tablet can target consumers who have difficulty swallowing conventional tablets or who want a no-water format. Crospovidone, mannitol, low-substituted hydroxypropyl cellulose, and flavor systems are common development tools.

The formulation must balance:

• Rapid disintegration.
• Adequate tablet strength.
• Low friability.
• Acceptable mouthfeel.
• Moisture protection.
• Taste masking.

A blister package is often preferable to a conventional bottle because orally disintegrating tablets are more moisture-sensitive. The packaging cost is higher, but the format can support premium pricing and a differentiated private-label SKU.

Chewable tablets

Chewables create a family-oriented opportunity. Mannitol, xylitol, sorbitol, sucralose, flavors, and taste-masking technologies can improve acceptance. The formula must control residual mouthfeel, grittiness, dental concerns, and active-ingredient bitterness.

Xylitol may support a sugar-free positioning, but its use requires careful control of gastrointestinal tolerability and manufacturing behavior. Polyol-rich formulations can be hygroscopic and may require moisture-barrier packaging.

Pediatric liquid

A loratadine oral solution or suspension can target pediatric dosing and consumers who cannot use tablets. The excipient system may include a vehicle, sweetener, flavor, buffer, viscosity modifier, and preservative where justified.

Key development questions include:

• Chemical stability across the labeled shelf life.
• Uniform dosing after storage.
• Pourability and syringe compatibility.
• Microbial quality.
• Preservative effectiveness.
• Palatability.
• Compatibility with dosing cups and oral syringes.

A sugar-free formulation using glycerin, sorbitol, or another suitable vehicle may broaden consumer appeal. The product must avoid excipients that create unnecessary risk for the intended pediatric population.

Fast-dissolving powder or granules

Single-dose sachets or stick packs could differentiate WAL-ITIN through portability and water-free administration. A powder system would require taste masking, humidity control, content uniformity, and dose delivery validation.

This format may be more valuable as a brand-extension platform than as a low-cost substitute for tablets. Sachet packaging, filling equipment, and moisture-barrier materials increase manufacturing expense.

What is the FDA regulatory status of WAL-ITIN?

Loratadine is an established OTC active ingredient under the FDA OTC monograph framework for antihistamine products. FDA’s final OTC monograph system is codified under the monograph structure in 21 C.F.R. Part 341 for cold, cough, allergy, bronchodilator, and antiasthmatic drug products.[2]

A compliant loratadine product generally requires:

• A permitted active ingredient and labeled dosage.
• Permitted indications and warnings.
• Appropriate directions for use.
• Compliance with current good manufacturing practice.
• Adequate stability and quality controls.
• Labeling that meets FDA OTC requirements.

Changes to dosage form, strength, route, active-ingredient combination, indication, or labeling can affect the regulatory pathway. An excipient change within an established dosage form may be handled through normal product development and quality processes, but the final product still must comply with applicable FDA requirements.

What is the Orange Book status of WAL-ITIN?

WAL-ITIN is generally an OTC private-label product rather than an NDA product with a conventional Orange Book patent-listing profile. The Orange Book primarily identifies approved prescription drug products and patent or exclusivity information associated with approved applications.[3]

The practical consequence is that a generic competitor normally does not challenge WAL-ITIN through a Paragraph IV certification. A Paragraph IV challenge applies to patents listed for a reference listed drug in an ANDA context. For a monograph-compliant loratadine OTC product, market entry usually depends on regulatory compliance, manufacturing capability, retailer access, and commercial economics.

When did loratadine lose exclusivity?

Loratadine’s original prescription and branded exclusivity periods expired before the current private-label market structure developed. Generic loratadine products entered the U.S. market in the early 2000s, and OTC generic competition expanded thereafter.[4]

Exclusivity issue	Commercial effect
Original active-ingredient patents	Expired
Original branded market exclusivity	Expired
Core loratadine generic entry	Established
WAL-ITIN product protection	Primarily trademark, supply, packaging, and retail positioning
New formulation protection	Possible only for specific, non-obvious innovations
Paragraph IV risk	Limited for a monograph-based private-label product

There is no meaningful business case for relying on basic loratadine composition claims. Any defensible IP strategy should focus on a differentiated dosage form, manufacturing process, package, device, or combination product.

Which companies compete with WAL-ITIN?

WAL-ITIN competes with national brands, retailer brands, pharmacy generics, and online sellers. The relevant competitive set includes Claritin, generic loratadine products, store-brand allergy products, and alternative non-sedating antihistamines such as cetirizine and fexofenadine.

Competitor category	Examples	Competitive basis
National brand	Claritin	Brand recognition and broad distribution
Retail private label	CVS, Costco, Amazon, Walmart, Walgreens	Price and convenience
Generic manufacturers	Perrigo, Teva, Dr. Reddy’s, various OTC suppliers	Cost and pharmacy availability
Alternative antihistamines	Zyrtec, Allegra, generic cetirizine, generic fexofenadine	Perceived efficacy, onset, duration, and consumer preference
Combination products	Loratadine with decongestant products	Multi-symptom positioning

The retailer has greater control when it owns the private-label brand and can coordinate shelf placement, digital search ranking, promotional pricing, and seasonal inventory.

What generic launch risks exist for WAL-ITIN?

The risk of new generic entry is structurally high because loratadine is an established, widely supplied OTC active ingredient. The principal competitive threats are not patent injunctions. They are price compression, retailer substitution, supply shortages, and product delisting.

A new supplier can compete by offering:

• Lower tablet cost.
• Higher manufacturing capacity.
• More reliable seasonal supply.
• A broader format portfolio.
• Improved packaging.
• A dual-source supply strategy.
• A formulation with lower defect and complaint rates.

For WAL-ITIN, supply continuity may be more commercially important than formulation exclusivity. Allergy demand is seasonal, and stockouts during peak pollen periods can shift consumers to competing brands quickly.

How strong is the patent estate for WAL-ITIN?

The patent estate is weak for the basic 10 mg loratadine tablet and potentially stronger for a genuinely differentiated formulation.

Asset	Likely protection strength
Basic loratadine tablet	Low
Standard excipient substitution	Low
Orally disintegrating format	Moderate if claims include technical performance
Taste-masked chewable	Moderate, dependent on composition and data
Pediatric liquid	Low to moderate unless stability or delivery technology is distinctive
Manufacturing process	Moderate if it produces reproducible, unexpected results
Packaging system	Moderate for a technically specific moisture-control solution
Trademark and retailer exclusivity	Commercially useful but not patent protection

A formulation patent should be supported by comparative data showing an advantage over conventional compositions. Relevant evidence may include dissolution, disintegration, stability, taste scores, content uniformity, friability, moisture uptake, and scale-up performance.

What licensing and manufacturing opportunities exist?

The most practical licensing opportunities are formulation technology and supply partnerships rather than rights to loratadine itself. Potential counterparties include excipient manufacturers, orally disintegrating tablet technology providers, contract development and manufacturing organizations, packaging suppliers, and private-label OTC manufacturers.

Manufacturing barriers are moderate. Loratadine tablets do not require biologic manufacturing, sterile processing, or complex device assembly. The main barriers are:

• Reliable low-dose blending.
• Seasonal production planning.
• Validated dissolution and content uniformity.
• Supplier qualification.
• Taste-masking capability for chewables.
• Moisture control for rapidly disintegrating products.
• FDA-compliant OTC quality systems.
• Retailer-specific packaging and serialization requirements.

A dual-source excipient strategy can reduce supply risk. Critical excipients should be qualified for equivalent functionality, not merely matched by chemical name. Switching between grades of microcrystalline cellulose, crospovidone, or magnesium stearate can alter compression, dissolution, and stability.

What revenue exposure and commercial upside does WAL-ITIN have?

WAL-ITIN revenue is exposed to retail price competition and seasonal demand. Public product-level revenue is generally not disclosed separately from Walgreens’ broader private-label and front-of-store categories.

Commercial upside can come from portfolio architecture:

1. A low-cost standard tablet for high-volume demand.
2. An orally disintegrating or chewable product with higher gross margin.
3. A pediatric liquid for household penetration.
4. Larger-count value packs for repeat seasonal users.
5. Travel-size or single-dose packaging.
6. Multipacks combining loratadine with complementary allergy products, subject to labeling and regulatory constraints.

The highest-return development path is usually a low-complexity extension that uses existing loratadine supply and established OTC labeling. A premium dosage form must generate enough incremental price or volume to cover tooling, packaging, stability, and retailer placement costs.

Key Takeaways

• WAL-ITIN is a private-label loratadine opportunity, not a product protected by a strong active-ingredient patent estate.
• Conventional tablet excipients should prioritize content uniformity, rapid disintegration, low cost, and manufacturing robustness.
• Orally disintegrating, chewable, pediatric liquid, and portable powder formats offer the clearest commercial extensions.
• Excipient innovation can support formulation patents only when linked to measurable technical advantages.
• Paragraph IV challenges are generally not the primary risk for a monograph-based OTC private-label product.
• Supply reliability, retailer economics, packaging, and seasonal availability are central competitive factors.
• The strongest IP strategy would target a differentiated dosage form, taste-masking system, manufacturing process, or moisture-control package.

FAQs

Is WAL-ITIN the same as Claritin?

WAL-ITIN uses loratadine, the same active ingredient used in Claritin products, but it is a separate private-label product and may differ in excipients, dosage form, packaging, and manufacturer.

Can a new loratadine excipient combination receive patent protection?

Yes, but routine substitution of common excipients is unlikely to provide strong protection. Patentability improves when the formulation produces documented advantages in taste, stability, dissolution, disintegration, content uniformity, or manufacturing performance.

Is loratadine suitable for an orally disintegrating tablet?

Yes. Loratadine’s low dose is compatible with an orally disintegrating format, but the formulation must address taste, mechanical strength, moisture sensitivity, disintegration time, and packaging.

Does WAL-ITIN face biosimilar competition?

No. Loratadine is a small-molecule drug, not a biologic. The relevant competitive threats are generic and private-label loratadine products, alternative antihistamines, and combination allergy medicines.

What is the most attractive commercial extension for WAL-ITIN?

An orally disintegrating or chewable 10 mg product is likely to offer the clearest balance between consumer differentiation, manageable development complexity, and premium pricing potential.

References

1. U.S. Food and Drug Administration. (n.d.). Loratadine drug facts and OTC antihistamine labeling. https://www.fda.gov
2. Electronic Code of Federal Regulations. (n.d.). 21 C.F.R. Part 341: Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-341
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/